Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Mesirow Institutional Investment Management Inc.

Mesirow Institutional Investment Management Inc. increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 29.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 934,234 shares of the biopharmaceutical company’s stock after acquiring an additional 215,130 shares during the period. Catalyst Pharmaceuticals comprises about 1.3% of Mesirow Institutional Investment Management Inc.’s holdings, making the stock its 27th biggest position. Mesirow Institutional Investment Management Inc.’s holdings in Catalyst Pharmaceuticals were worth $14,471,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CPRX. Janus Henderson Group PLC increased its position in Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after purchasing an additional 1,587,794 shares during the last quarter. Boston Partners lifted its stake in shares of Catalyst Pharmaceuticals by 965.2% in the 4th quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock valued at $25,610,000 after purchasing an additional 1,396,930 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of Catalyst Pharmaceuticals by 101.1% in the 1st quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock valued at $16,924,000 after acquiring an additional 533,802 shares during the period. Finally, Bridger Management LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $3,102,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the transaction, the insider now owns 12,369 shares in the company, valued at $227,836.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Carmen Jeffrey Del sold 36,058 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares in the company, valued at $227,836.98. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 208,599 shares of company stock worth $4,139,372. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $19.74 on Wednesday. The business’s fifty day moving average is $17.71 and its 200-day moving average is $16.35. Catalyst Pharmaceuticals, Inc. has a 1 year low of $11.55 and a 1 year high of $20.87. The stock has a market cap of $2.33 billion, a PE ratio of 36.56, a price-to-earnings-growth ratio of 3.30 and a beta of 0.70.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The business had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. Equities research analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on CPRX. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $29.50.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.